0
variable(s) selected download| Category | Variable name | variable label (+ explanatory notes) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient data | gebdat | Date of birth | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | gesl | Sex |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | iacr | Counts following IACR rules for reporting incidence |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | incdat | Incidence date
+
The incidence date is the date of the first histological or cytological confirmation of the tumour. It cannot be later than the start of treatment. If treatment begins before histological confirmation, the incidence date is the date of clinical diagnosis. It must always fall within three months of the first clinical visit related to this tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | incjr | Year of incidence
+
The incidence date is the date of the first histological or cytological confirmation of the tumour. It cannot be later than the start of treatment. If treatment begins before histological confirmation, the incidence date is the date of clinical diagnosis. It must always fall within three months of the first clinical visit related to this tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | ink_ses | Median income in postal code area as a proxy for socioeconomic status (SES)
+
Available from 2010. Socioeconomic status (SES) reflects an individual's social position, which strongly influences health and is linked to life expectancy in good health. Research on SES and health typically uses indicators such as education, income, occupation, and material wealth. This variable uses income as a proxy for SES.
Income data by postal code area were obtained from Statistics Netherlands (CBS), with 2019 as the reference year, downloaded on 16 October 2023 via https://www.cbs.nl/nl-nl/dossier/nederland-regionaal/geografische-data
/gegevens-per-postcode.
Income is defined as the median disposable household income, adjusted for household size and composition. For each area, the median standardised household income was compared to the national distribution and classified into one of five groups: low, lower-middle, middle, upper-middle, or high. Income thresholds (in euros) are available at: https://www.cbs.nl/nl-nl/longread/diversen/2023/statistische-gegevens-per-vierkant-en-postcode-2022-2021-2020-2019/4-beschrijving-cijfers. Because postal code areas often have few households, CBS also
considered the 99% confidence interval of the median income. If this interval spans multiple groups, a new category was created to reflect the range (e.g., 'low to lower-middle'). Categories may partially overlap due to this approach. If the median income is based on fewer than 10 households, it is classified as 'unclassifiable'. CBS originally defined 12 income categories.
For this variable, these were reduced to three to simplify analysis and remove overlaps.
Key considerations:
- Income is a snapshot and does not reflect accumulated wealth.
- Data are aggregated by postal code area, which may include substantial variation.
- Household income is strongly age-dependent; analyses should compare individuals within the same age group.
- Median disposable income is considered valid for up to 10 years before and after the reference year (2019).
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | leeft | Age at incidence date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | mal | Previous or subsequent malignancies
+
Selection of malignancies to specify in the request:
-Period: Previous and/or subsequent malignancies, or based on a defined timeframe before or around the incidence date.
-Type: All cancer types in the NCR, or all malignant/invasive (excluding skin BCC), or a selection of specific tumour types.
NKR database content with full availability:
Period: Nationwide complete from 1989.
Exclusion criteria:
- Patients residing abroad at the time of incidence
- Basal cell carcinomas of skin and lip
- Second primary invasive and second non-invasive squamous cell carcinomas of the skin
- Adenocarcinoma in situ/high-grade dysplasia of colon, rectosigmoid and rectum
- Carcinoma in situ of the cervix
- Benign/borderline tumours, except: CNS tumours from 2001, Borderline ovarian tumours, AL amyloidosis from 2017, Polymorphic PTLD
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | mal_incdat | Incidence date of previous or subsequent malignancy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | mal_int | Interval between incidence date and date of previous or subsequent malignancy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | mal_tumsoort | Tumour type of previous or subsequent malignancy
+
Refers to the NCR tumour classification based on site, morphology, and behaviour. For more information, see: https://iknl.nl/nkr/registratie/tumorindeling
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | ovldat | Date of death | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | post_cijf | Numeric part of the patient's postal code at the time of incidence | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | vit_stat_dat | Date of vital status
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | vit_stat_int | Interval between incidence date and date of vital status (days)
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patient data | vit_stat | Vital status
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | topo | Topography excluding sublocation
+
Location of the primary tumour according to ICD-O-3.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | topo_sublok | Topography including sublocation
+
Location and sublocation of the primary tumour according to ICD-O-3.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | later | Laterality |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | morf | Morphology
+
Histological type of the tumour (first four digits of the ICD-O morphology code) according to ICD-O-3.2.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | morf_cat | Morphology (categories) |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | gedrag | Behaviour
+
Tumour behaviour (fifth digit of the ICD-O morphology code).
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | diffgrad | (Differentiation) grade
+
Tumour differentiation grade (sixth digit of the ICD-O morphology code)
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | ct | cT (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | cn | cN (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | cm | cM (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | pt | pT (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | pn | pN (TNM)
+
The TNM classification uses the edition applicable at the time of incidence.
Meaning of the last character in pN:
S: Result based only on sentinel node examination (sn)
I: Isolated tumour cells (ITC)
M: Micrometastases (mi)
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | pm | pM (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | cstadium | Clinical TNM stage
+
cstadium: The clinical stage is based on cTNM, which is derived from information available before (neo-adjuvant) treatment, including findings during surgery (if not treated neo-adjuvantly) that influence the treatment plan.
Meaning of "X" (unknown): Stage cannot be calculated, e.g., TX/NX/M0. Meaning of "M" (missing): Indicates TNM not recorded, possibly due to incomplete registration or use of EoD staging instead of TNM. Meaning of "NVT" (not applicable): TNM staging does not apply to this tumour type for the given incidence period.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | pstadium | Pathological TNM stage
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
pstadium: The pathological (post-surgical) stage is based on pT, pN and pM. Also in case of pre-surgical therapy, pT and pN are used (ypT and ypN). When no tumour is detectable after pre-surgical therapy, this is shown as pstadium=0.
pM: Indicates whether there is pathological confirmation of distant metastases. There may be distant metastases that are not pathologically confirmed, which are therefore not included in the calculation for this variable.
Meaning of "X" (unknown): Stage cannot be calculated, e.g., TX/NX/M0.
Meaning of "M" (missing): Indicates TNM not recorded, possibly due to incomplete registration or use of EoD staging instead of TNM.
Meaning of "NVT" (not applicable): TNM staging does not apply to this tumour type for the given incidence period.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | stadium | TNM stage
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
Stadium: Based on pTNM supplemented by cTNM to best reflect the actual stage at diagnosis. Priority is given to pTNM values. If surgery did not occur, pTNM is unknown, or pre-surgical therapy was given (pTNM becomes ypTNM), cTNM values are used.
Meaning of "X" (unknown): Stage cannot be calculated, e.g., TX/NX/M0.
Meaning of "M" (missing): Indicates TNM not recorded, possibly due to incomplete registration or use of EoD staging instead of TNM.
Meaning of "NVT" (not applicable): TNM staging does not apply to this tumour type for the given incidence period.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | ond_lymf | Number of regional lymph nodes examined
+
All lymph nodes examined as part of initial diagnostics and treatment combined.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | pos_lymf | Number of positive regional lymph nodes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | diag_basis | Basis for diagnosis
+
Non-microscopic confirmation:
0 = death certificate only
1 = clinical examination only (medical history and physical)
2 = clinical diagnostic tests, exploratory surgery or autopsy (without microscopic confirmation)
4 = specific biochemical and/or immunological laboratory tests.
Microscopic confirmation:
5 = haematological (bone marrow cytology, e.g., bone marrow aspiration, blood smear) or cytological confirmation of primary tumour or metastases, or definite microscopic confirmation but unclear whether cytology or histology
6 = histological confirmation of metastases only, including at autopsy
7 = histological confirmation of primary tumour, or unclear whether histology refers to primary tumour or
metastasis, including autopsy with histology.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | dlco | DLCO (%) relative to the predicted normal value
+
Available for 2020-2022. Refers to the lung diffusion capacity for carbon monoxide (DLCO). The measured value is expressed as a percentage of the predicted value for a healthy individual. DLCO depends on sex, age, height and haemoglobin level.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | fev1 | FEV-1 (%) relative to the predicted normal value
+
Available for 2020-2022. Refers to the forced expiratory volume in one second (FEV1) measured from total lung capacity, expressed as a percentage of the predicted normal value. This predicted value depends on factors such as sex, age and height.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | klin_tum_afm | Maximum clinical diameter of the primary tumour (mm)
+
Available from 2015. Refers to the maximum clinical diameter of the primary tumour as measured on CT, or on PET(/CT) if no CT was available. For multifocal tumours, the size of the largest lesion is recorded.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | longtum_voor_int | Interval between the incidence date of the previous primary lung tumour and the current tumour (days)
+
If there is a history of multiple primary lung tumours, the interval described refers to the period since the last, most recently occurring lung tumour prior to the current lung tumour. All previous lung cancer diagnoses are taken into account, including non invasive lung tumours, up to the day before the current lung tumour. The Netherlands Cancer Registry (NCR) is complete from 1989 onwards; therefore, incidences prior to that year may have been missed.
Incident dates are defined as the dates of the first histological or cytological confirmation of the primary tumours.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | longtum_voor | History of a previous primary lung tumour
+
Indicates whether a primary lung tumour occurred prior to the current lung tumour. All previous lung cancer diagnoses, including non invasive lung tumours, are considered up to the day before the current diagnosis. The Netherlands Cancer Registry (NCR) is considered complete from 1989 onwards; earlier incidents may be missing.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | m1c | Staging of M1c tumours according to TNM9
+
With the introduction of TNM9, which has been in force since January 2025, lung tumours staged as M1c (TNM8) are subdivided into M1c1 and M1c2, depending on the number of extrathoracic organ systems with distant metastases. In this variable, this distinction is applied retrospectively to earlier incidence years.
Only available for lung tumours with clinical M1c (TNM8) from 2017 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_incdat | Incidence date of metastasis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_int | Interval between incidence date and date of metastasis (days)
+
The incidence date is defined as the date of the first histological or
cytological confirmation of the primary tumour.
The metastasis date refers to the first histological or cytological confirmation of the
metastasis. If histological confirmation does not occur within three
months, the clinical diagnosis date is used. Consequently, the
metastasis date may precede the primary tumour incidence date by up
to three months.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_topo_sublok | Topography including sublocation of metastasis
+
Metastasis location according to ICD-O-3. Metastatic sites have been recorded nationwide since 2008. For distant metastases at more than three sites, C768 was coded up to 2014 to indicate more than three locations. In 2017/2018 C768 may indicate more than four locations.
Explanation for records where both cM and pM show no metastases despite metastatic sites being recorded at diagnosis: cTNM is based on information available before (neo-adjuvant) treatment, including findings during surgery (if not treated neo-adjuvantly) that influence the treatment plan. pM indicates whether pathological
confirmation exists for distant metastases. If metastases are detected during or after neo-adjuvant treatment, TNM is not updated, but metastasis locations are recorded.
If the dataset includes metastasis locations after progression: only new or enlarged metastases are recorded, not all existing ones. C809 is coded for clinical progression when the site is unknown.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_topo | Topography excluding sublocation of metastasis
+
Metastasis location according to ICD-O-3. Metastatic sites have been recorded nationwide since 2008. For distant metastases at more than three sites, C768 was coded up to 2014 to indicate more than three locations. In 2017/2018 C768 may indicate more than four locations.
Explanation for records where both cM and pM show no metastases despite metastatic sites being recorded at diagnosis: cTNM is based on information available before (neo-adjuvant) treatment, including findings during surgery (if not treated neo-adjuvantly) that influence the treatment plan. pM indicates whether pathological
confirmation exists for distant metastases. If metastases are detected during or after neo-adjuvant treatment, TNM is not updated, but metastasis locations are recorded.
If the dataset includes metastasis locations after progression: only new or enlarged metastases are recorded, not all existing ones. C809 is coded for clinical progression when the site is unknown.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_lok_aantal | Number of topographic locations with metastases present
+
Metastases diagnosed prior to progression and up to a maximum of 91 days after the incidence date of the primary tumour.
Metastatic sites have been recorded nationwide since 2008 – before that time, metastases may have been known but not registered. Therefore, this variable is defined from incidence year 2008 onward.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_diag_basis | Basis for metastasis diagnosis |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_bijnier | Adrenal metastasis/metastases present
+
Yes, if adrenal metastases were diagnosed prior to disease progression and up to a maximum of 91 days after the incidence of the primary tumour.
Metastatic sites have been recorded nationwide since 2008. Before that time, metastases may have been known but not documented. Therefore, for the period prior to 2008, only value 1/yes is available.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_bot | Bone metastasis/metastases present
+
Yes, if bone metastases were diagnosed prior to disease progression and up to a maximum of 91 days after the incidence of the primary tumour.
Metastatic sites have been recorded nationwide since 2008. Before that time, metastases may have been known but not documented. Therefore, for the period prior to 2008, only value 1/yes is available.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_cns | CNS metastasis/metastases present
+
Yes, if CNS metastases were diagnosed prior to disease progression and up to a maximum of 91 days after the incidence of the primary tumour.
Metastatic sites have been recorded nationwide since 2008. Before that time, metastases may have been known but not documented. Therefore, for the period prior to 2008, only value 1/yes is available.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_later | Laterality of metastasis |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_lever | Liver metastasis/metastases present
+
Yes, if liver metastases were diagnosed prior to disease progression and up to a maximum of 91 days after the incidence of the primary tumour.
Metastatic sites have been recorded nationwide since 2008. Before that time, metastases may have been known but not documented. Therefore, for the period prior to 2008, only value 1/yes is available.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_long | Lung metastasis/metastases present
+
Yes, if lung metastases were diagnosed prior to disease progression and up to a maximum of 91 days after the incidence of the primary tumour.
Metastatic sites have been recorded nationwide since 2008. Before that time, metastases may have been known but not documented. Therefore, for the period prior to 2008, only value 1/yes is available.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_lymf | Non-regional lymph node metastasis/metastases present
+
Yes, if lymph node metastases were diagnosed prior to disease progression and up to a maximum of 91 days after the incidence of the primary tumour.
Metastatic sites have been recorded nationwide since 2008. Before that time, metastases may have been known but not documented. Therefore, for the period prior to 2008, only value 1/yes is available.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_overig | Other metastasis/metastases present
+
Yes, if metastases at sites other than the adrenal glands, bone, CNS, lymph nodes, or pleura were diagnosed prior to disease progression and up to a maximum of 91 days after the incidence of the primary tumour.
Metastatic sites have been recorded nationwide since 2008. Before that time, metastases may have been known but not documented. Therefore, for the period prior to 2008, only value 1/yes is available.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | meta_pleura | Pleural metastasis/metastases present
+
Yes, if pleural metastases were diagnosed prior to disease progression and up to a maximum of 91 days after the incidence of the primary tumour.
Metastatic sites have been recorded nationwide since 2008. Before that time, metastases may have been known but not documented. Therefore, for the period prior to 2008, only value 1/yes is available.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | multifoc | Tumour multifocality |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | mut | Detected mutations
+
In the NCR, it is not recorded which mutations a tumour has been tested for. If no testing has been performed, it is therefore possible that the mutation is nevertheless present.
Not all types of mutations are recorded in the NCR. There is a code list specifying which mutations are recorded, from when, and according to which definition. Over time, this code list has been refined. For example, EGFR was initially recorded as EGFR-NOS, and later EGFR subtypes were introduced. For BRAF and MET, the definition was refined to BRAF-V600E and MET exon 14 skipping.
This item has been routinely registered in the NKR since 2015. Registration is incomplete for two hospitals. EGFR was also routinely registered in the period 2011-2013 (incompletely in 2014).
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | mut_action | Actionable mutations
+
A number of mutations may, depending on disease stage, be eligible for treatment with targeted therapy. However, treatment guidelines have changed over the years. This variable indicates whether targeted therapy was available as standard treatment for the specific mutation in the year concerned. It is, however, possible that this therapy was already being used earlier, for example within the context of clinical trials or an expanded access programme.
Note: use this classification with caution. Particularly for the less specific categories, these codes may also include subvariants which were later found (or may later prove) not to be amenable to effective treatment with targeted therapy. In general, mutation-informed, tumour-targeted treatment is still a rapidly evolving field.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | mut_dat | Date of mutation testing | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | mut_int | Interval between incidence date and date of mutation testing (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | pa_tum_afm | Pathological maximum diameter of the primary tumour (mm)
+
Available since 2015.
The pathological measurement of the primary tumour based on lung surgery. Only the invasive component of the tumour is taken into account.
In the case of multiple lung surgeries, and therefore multiple pathology reports, this variable shows the maximum pathological tumour size.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | pdl1_cat | PD-L1 receptor expression (%) in categories
+
Available since 2018.
When multiple PD-L1 tests have been performed, only the highest value is recorded.
Note: When a pathologist codes >50%, we record 50-89%. Therefore, the 50-89% group may include tumours that in reality have a score of 90-100%.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | smplc | Synchronous multiple primary lung cancer (sMPLC)
+
Synchronous multiple primary lung cancer (sMPLC) is defined as another primary lung cancer diagnosed within 90 days before or after the index diagnosis.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumour data | sulc_sup | Superior sulcus
+
Available from 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | contact_zkh1 | Hospital of first contact regarding malignancy
+
The first hospital visited by the patient for symptoms related to the malignancy, and where, based on that visit, a (suspected) malignancy is determined.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | contact_zkh1_consult_int | Interval between incidence date and first hospital consultation
+
Available since 2015. The first hospital visited by the patient for symptoms related to the malignancy.
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | diag_reden | Reason for diagnostic assessment
+
Available from 2018.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | ebus | EBUS performed
+
EBUS has been routinely recorded since around 2010.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | ebus_uitslag | Most unfavourable biopsy/puncture result from EBUS
+
Reports the most unfavourable result from any biopsies/aspirations taken during EBUS. EBUS has been routinely recorded since around 2010.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | eus | Endoscopic ultrasound (EUS) performed
+
EUS has been routinely recorded since around 2010.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | eus_uitslag | Most unfavourable biopsy/puncture result from EUS
+
This variable reports the most unfavourable result from any biopsies/aspirations taken during EUS. EUS has been routinely recorded in the NCR since around 2010.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | hersendiag | Brain imaging performed during initial diagnosis and treatment
+
MRI or CT scan. Available from 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | hersendiag_dat | Date of brain imaging
+
Date of first MRI, or date of first CT if no MRI was performed.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | hersendiag_int | Interval between incidence date and date of brain imaging (days)
+
Based on the date of the first MRI, or the first CT if no MRI was performed. Available from 2015. The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | mdo_voor_ther_dat | Date of the final multidisciplinary team meeting (MDT) before treatment commenced
+
Available since 2022.
In the case of multiple MDTs prior to therapy, this variable only shows the date of the last MDT.
For the start of therapy, this variable looks at all therapies: these may also include, for example, palliative treatments.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | mdo_voor_ther_int | Interval between incidence date and date of the final MDT before treatment (days)
+
Available since 2022.
The incidence date is defined as the date of the first histological or cytological
confirmation of the primary tumour.
In the case of multiple MDTs prior to therapy, this variable only shows the date of the last MDT.
For the start of therapy, this variable looks at all therapies: these may also include, for example, palliative treatments.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | mdo_voor_ther | Discussed in the multidisciplinary team (MDT) before starting treatment
+
Available from 2022.
In this variable, the start of therapy includes all types of therapies: these may also include palliative treatments.
If no treatment was administered at all, or if the start date of the first treatment is unknown, this variable is by definition assigned the value 0 (no yes). Consequently, the proportion of patients with a value of 1 may be underestimated.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | mdo_voor_ther_zkh | Hospital of the final MDT before treatment
+
Available since 2022.
In the case of multiple MDTs prior to therapy, this variable only shows the date of the last MDT.
For the start of therapy, this variable looks at all therapies: these may also include, for example, palliative treatments.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | mediast | Mediastinoscopy performed |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | mediast_uitslag | Most unfavourable biopsy result from mediastinoscopy
+
Reports the most unfavourable result from any biopsies taken during mediastinoscopy.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | mol_diag_dat | Date of molecular diagnostics
+
Available from 2016.
The date of molecular diagnostics is defined as the date of the first positive result (of tumour markers recorded in the NKR). In the case of a negative result, this is the date of the most recent test result.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | mol_diag_int | Interval incidence date and date of molecular diagnostics
+
Available from 2016.
The date of molecular diagnostics is defined as the date of the first positive result (of tumour markers recorded in the NKR). In the case of a negative result, this is the date of the most recent test result.
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | mol_diag_type | Type of molecular diagnostic testing
+
Available from 2023. If multiple examinations were performed, the most extensive one is recorded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | mol_diag_zkh | Hospital of molecular diagnostic testing
+
Available from 2016.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | navbroncho_dat | Date of navigational bronchoscopy
+
Available from 2023.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | navbroncho_int | Interval between incidence date and date of navigational bronchoscopy (days)
+
Available from 2023. The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | navbroncho_uitslag | Result of navigational bronchoscopy
+
Available from 2023. Navigation during this bronchoscopy is CT-guided. If multiple navigation bronchoscopies were performed, only the final one conducted as part of the diagnostic process is recorded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | navbroncho_zkh | Hospital where the navigational bronchoscopy was performed
+
Available from 2023.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | ther_diag_basis | Basis for diagnosis prior to starting treatment
+
Available from 2020. Refers to the basis of diagnosis, established prior to initiating first treatment or prior to the decision not to treat.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | tt_punctie | Transthoracic biopsy performed
+
Availablesince 2017.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | tt_punctie_uitslag | Most informative result from transthoracic biopsy
+
If multiple transthoracic needle biopsies were performed, this variable captures the most informative result. Available for 2017-2022.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Process data | zkh_patnum | Patient number in hospital | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | comorb_onco | Oncological comorbidity present
+
Classification based on the presence of a known non-metastatic invasive tumour in the five years prior to diagnosis, or a previously metastatic primary tumour at any point in the entire medical history up to 30 days after the incidence date. Basal cell and squamous cell carcinomas of the skin are not included.
The NCR is not complete in the registration of metachronous metastases. For many tumour types, these have only been recorded in recent years, either on a project basis or structurally, this variable may therefore be incorrectly recorded as 0.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk factors | perf_stat | WHO performance status before start of therapy
+
WHO performance status before starting therapy. If the Karnofsky score is noted in the medical record, it is converted to WHO score as described in Ma et al. 2010 - Interconversion of three measures of performance status: An empirical analysis. Performance status has been recorded for lung cancer since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemo | Systemic chemotherapy classified as pre- or post-surgical
+
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local surgical procedures (e.g. polypectomy, excision biopsy, TUR, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemo_code[1-n] | Code of systemic chemotherapy[1-n]
+
Systemic therapy drugs are recorded in the NCR using codes from the Anatomical Therapeutic Chemical classification system (ATC codes). Systemic therapy was not always recorded in detail; particularly before 2015, non-specific codes were used.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemo_immuno | Systemic chemo-immunotherapy administered
+
Applies only to chemotherapy and immunotherapy administered simultaneously: if both were given sequentially and there is no overlap, this is not considered chemo-immunotherapy (value 0).
In some cases, the start and/or end date of chemotherapy or immunotherapy is unknown, making it impossible to determine whether there was overlap; in that case, value 9 is displayed.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemo_start_int[1-n] | Interval incidence date and start date of systemic chemotherapy (days)[1-n]
+
The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemo_stop_int[1-n] | Interval incidence date and stop date of systemic chemotherapy (days)[1-n]
+
The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemo_startdat[1-n] | Start date of systemic chemotherapy[1-n] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemo_stopdat[1-n] | Stop date of systemic chemotherapy[1-n] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemo_type | Type of systemic chemotherapy
+
For registrations prior to 2018, the NCR commonly documented only the administration of systemic chemotherapy, without indicating the specific regimen. Consequently, this variable is more often coded as 9 (unknown) in earlier years.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemo_zkh[1-n] | Hospital where systemic chemotherapy was administered[1-n] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemort | Chemoradiation classified as pre- or post-surgical
+
Both chemotherapy and radiotherapy were part of the treatment, and based on the type and combination of both treatments, this likely represents chemoradiation. The chemotherapy and radiotherapy components also count towards the variables for systemic chemotherapy and radiotherapy.
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local procedures (e.g. tumour destruction, excision biopsy, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
Available since 2010
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemort_start_int | Interval between incidence date and start date of chemoradiotherapy (days)
+
The incidence date is the date of the first histological or cytological confirmation of the primary lung tumour.
It concerns the interval in days to the start date of the first chemotherapy or radiotherapy treatment that is part of chemoradiation.
Available since 2010.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemort_stop_int | Interval between incidence date and end date of chemoradiotherapy (days)
+
The incidence date is the date of the first histological or cytological confirmation of the primary lung tumour.
It concerns the interval in days up to the final end date of all chemotherapy and radiotherapy treatments that are part of chemoradiation.
Available since 2010.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemort_startdat | Start date of chemoradiotherapy
+
This concerns the start date of the first chemotherapy or radiotherapy treatment that is part of chemoradiation.
Available since 2010.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemort_stopdat | End date of chemoradiotherapy
+
This concerns the final end date of all chemotherapy and radiotherapy treatments that are part of chemoradiation.
Available since 2010.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chemort_type | Type of chemoradiation
+
Both chemotherapy and radiotherapy were part of the treatment, and based on the type and combination of both treatments, this likely represents chemoradiation. The chemotherapy and radiotherapy components also count towards the variables for systemic chemotherapy and radiotherapy.
The type of chemoradiation was determined by assessing whether chemotherapy and radiotherapy were administered overlapping (concurrent) or sequentially. It may occur that the start and/or end date of a treatment is missing. In such cases, the 30-day rule was applied: if there are 30 days or fewer between the start of chemotherapy and the start of radiotherapy, or between the end of chemotherapy and the end of radiotherapy, this is considered concurrent. A difference of more than 30 days is classified as sequential. When no start and/or end dates are available at all for determining overlap or applying the 30-day rule, value 9 (unknown) applies.
Within a single episode, multiple chemotherapy and radiotherapy treatments may occur, which may result in the presence of more than one type of chemoradiation. In such cases, the following prioritisation was applied: concurrent, unknown (as these cases may potentially also be concurrent),sequential.
Available since 2010.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir | Surgery performed
+
Lung surgery performed with the aim of removing the primary tumour, excluding diagnostic procedures, incidental findings (see the variables related to other surgery), and additional resections.
Note: up to and including 2015, fewer details of surgical procedures were recorded in the NKR, which means it cannot always be determined whether a wedge resection was diagnostic or not. Therefore, in that period, it may occur that a diagnostic procedure is classified as lung surgery.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_code[1-3] | Surgery code[1-3]
+
Lung surgery performed with the aim of removing the primary tumour, excluding diagnostic procedures, incidental findings (see the variables related to other surgery), and additional resections.
Note: up to and including 2015, fewer details of surgical procedures were recorded in the NKR, which means it cannot always be determined whether a wedge resection was diagnostic or not. Therefore, in that period, it may occur that a diagnostic procedure is classified as lung surgery.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_dat[1-3] | Date of surgery[1-3] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_int[1-3] | Interval between incidence date and date of surgery (days)[1-3]
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary lung tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_rad_laatste | Radicality after the final surgical procedure
+
Describes the final resection radicality determined on the basis of the last surgical procedure performed with the intention to remove the primary lung tumour.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_rad[1-3] | Radicality of surgery[1-3]
+
Available from 2016.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_tech[1-3] | Surgical technique[1-3]
+
Available from 2010. In the NCR, the distinction between robot-assisted surgery (RATS) and conventional thoracoscopic or video-assisted surgery (VATS) has only been recorded since 2018. Before that, both techniques were registered as scopic.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_toeval | Tumour was an incidental finding during surgery for another indication |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_type[1-3] | Type of surgery[1-3]
+
Lung surgery performed with the aim of removing the primary tumour, excluding diagnostic procedures, incidental findings (see the variables related to other surgery), and additional resections.
Note: up to and including 2015, fewer details of surgical procedures were recorded in the NKR, which means it cannot always be determined whether a wedge resection was diagnostic or not. Therefore, in that period, it may occur that a diagnostic procedure is classified as lung surgery.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | chir_zkh[1-3] | Hospital where surgery was performed[1-3] |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | geen_syst_ther_reden | Reason why no systemic therapy was administered
+
Available from 2021 onward and only for stage IV tumours for which exclusively palliative radiotherapy was administered.
If no therapy has been performed at all, the variable geen_ther_reden can be consulted.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | geen_ther_reden | Reason no treatment was given
+
Available from 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | immuno | Systemic immunotherapy classified as pre- or post-surgical
+
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local procedures (e.g. tumour destruction, excision biopsy, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | immuno_code[1-n] | Code for systemic immunotherapy[1-n]
+
Systemic therapy drugs are recorded in the NCR using codes from the Anatomical Therapeutic Chemical classification system (ATC codes). Systemic therapy was not always recorded in detail; particularly before 2015, non-specific codes were used.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | immuno_start_int[1-n] | Interval incidence date and start date of systemic immunotherapy (days)[1-n]
+
The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | immuno_stop_int[1-n] | Interval incidence date and stop date of systemic immunotherapy (days)[1-n]
+
The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | immuno_startdat[1-n] | Start date of systemic immunotherapy[1-n] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | immuno_stopdat[1-n] | Stop date of systemic immunotherapy[1-n] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | immuno_zkh[1-n] | Hospital where systemic immunotherapy was administered[1-n] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | meta_chir | Surgery targeting metastases performed |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | meta_chir_code | Code for surgery targeting metastases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | meta_rt_code | Code for radiotherapy targeting metastases
+
This variable indicates the organ targeted by radiotherapy.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | meta_rt_dat | Date of radiotherapy targeting metastases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | meta_chir_dat | Date of surgery targeting metastases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | meta_chir_int | Interval between incidence date and date of surgery targeting metastases (days) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | meta_rt_int | Interval between incidence date and date of radiotherapy targeting metastases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | meta_rt | Radiotherapy targeting metastases performed |
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | mut_target_code[1-n] | Code for mutation-targeted systemic therapy[1-n]
+
Only the targeted therapies used in lung cancer with specific mutations - such as ALK, BRAF, or EGFR - are included.
Systemic therapy drugs are recorded in the NCR using codes from the Anatomical Therapeutic Chemical classification system (ATC codes). Systemic therapy was not always recorded in detail; particularly before 2015, non-specific codes were used.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | mut_target_start_int[1-n] | Interval incidence date and start date of mutation-targeted therapy (days)[1-n]
+
The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | mut_target_stop_int[1-n] | Interval incidence date and stop date of mutation-targeted therapy (days)[1-n]
+
The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | mut_target_startdat[1-n] | Start date of mutation-targeted systemic therapy[1-n] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | mut_target_stopdat[1-n] | Stop date of mutation-targeted systemic therapy[1-n] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | mut_target | Mutation-targeted systemic therapy classified as pre- or postsurgical
+
Only the targeted therapies used in lung cancer with specific mutations - such as ALK, BRAF, or EGFR - are included.
In determining pre- and post-surgical therapy, the sequence of procedures recorded in the NKR is used. The first surgical resection is taken as the reference point. Local surgical procedures (such as tumour destruction, excision biopsy, photodynamic therapy, electrocauterisation, cryosurgery, or radiofrequency ablation) are not included in this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | mut_target_zkh[1-n] | Hospital where mutation-targeted systemic therapy was administered[1-n] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | overig_chir | Other surgical procedures performed
+
Defined as surgical procedures related to lung cancer, excluding resections intended to remove the primary tumour (see variables concerning lung surgery).
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | overig_target_code[1-n] | Code for other systemic targeted therapy[1-n]
+
This variable concerns systemic targeted therapy, excluding immunotherapy and mutation-directed targeted therapy.
Systemic therapy drugs are recorded in the NCR using codes from the Anatomical Therapeutic Chemical classification system (ATC codes). Systemic therapy was not always recorded in detail; particularly before 2015, non-specific codes were used.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | overig_chir_dat | Date of other surgical procedures | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | overig_chir_int | Interval between incidence date and date of other surgical procedures (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary lung tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | overig_target_start_int[1-n] | Interval incidence date and start date of other targeted therapy (days)[1-n]
+
The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | overig_target_stop_int[1-n] | Interval incidence date and stop date of other targeted therapy (days)[1-n]
+
The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | overig_target_startdat[1-n] | Start date of other systemic targeted therapy[1-n] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | overig_target_stopdat[1-n] | Stop date of other systemic targeted therapy[1-n] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | overig_target | Other systemic targeted therapy performed
+
This variable concerns systemic targeted therapy, excluding immunotherapy and mutation-directed targeted therapy.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | overig_chir_type | Type of other surgical procedures
+
Defined as surgical procedures related to lung cancer, excluding resections intended to remove the primary tumour (see lung surgery variables). If multiple such procedures were performed, only the first is recorded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | overig_chir_zkh | Hospital where other surgical procedures were performed | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | overig_target_zkh[1-n] | Hospital where other systemic targeted therapy was administered[1-n] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | pci | Prophylactic cranial irradiation (PCI) performed
+
Defined as cranial irradiation for patients without documented brain metastases, with the aim of reducing the risk of developing brain metastases.
Available nationwide from 2007.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | pci_start_int | Interval between incidence date and start date of PCI (days)
+
The incidence date is the date of the first histological or cytological confirmation of the primary lung tumour.
If multiple PCIs have been performed, this variable reflects the interval to the end date of the first PCI.
Nationally available from 2007 onward.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | pci_stop_int | Interval between incidence date and end date of PCI (days)
+
The incidence date is the date of the first histological or cytological confirmation of the primary lung tumour.
If multiple PCIs have been performed, this variable reflects the interval to the start date of the first PCI.
Nationally available from 2007 onward.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | pci_startdat | Start date of PCI
+
If multiple PCIs have been performed, this variable reflects the interval to the start date of the first PCI.
Nationally available from 2007 onward.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | pci_stopdat | End date of PCI
+
If multiple PCIs have been performed, this variable reflects the interval to the end date of the first PCI.
Nationally available from 2007 onward.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt | Radiotherapy classified as pre- or post-surgical
+
This variable refers to radiotherapy targeting the primary tumour.
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local procedures (e.g. tumour destruction, excision biopsy, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_frac_dosis[1-3] | Radiotherapy dose per fraction (Gy)[1-3]
+
Refers to radiotherapy targeting the primary tumour.
Available since 2020
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_dosis[1-3] | Total radiotherapy dose (Gy)[1-3]
+
Refers to radiotherapy targeting the primary tumour.
Available since 2020
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_frac[1-3] | Number of radiotherapy fractions[1-3]
+
Refers to radiotherapy targeting the primary tumour.
Available since 2020
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_stop_int[1-3] | Interval between incidence date and end date of radiotherapy (days)[1-3]
+
Refers to radiotherapy targeting the primary tumour.
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour
Available since 2010
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_start_int[1-3] | Interval between incidence date and start date of radiotherapy (days)[1-3]
+
Refers to radiotherapy targeting the primary tumour.
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour
Available since 2010
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_startdat[1-3] | Start date of radiotherapy[1-3]
+
Refers to radiotherapy targeting the primary tumour.
Available since 2010
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_stopdat[1-3] | End date of radiotherapy[1-3]
+
Refers to radiotherapy targeting the primary tumour.
Available since 2010
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_type[1-3] | Type of radiotherapy[1-3]
+
Describes for each radiotherapy treatment whether it is palliative, radical (with curative intent), or substandard (cannot be classified as palliative or radical according to existing guidelines). This concerns radiotherapy targeting the primary tumour. A combination of external beam radiotherapy and proton therapy is always considered radical. In addition, the (total) dose, the number of fractions, and the duration of the radiotherapy were taken into account. If the type cannot be determined based on this information, for example, because it is not (fully) recorded, the stage of the lung tumour is used instead; for stages 0, I, and II, radical treatment is assumed, and for stage IV, palliative radiotherapy.
Available since 2010. Until 2020, the number of fractions and the radiotherapy dose were not yet recorded in the NKR, so for earlier incidence years this variable is based only on the duration of the radiotherapy treatment and the tumour stage, and may therefore be less reliable.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | rt_zkh[1-3] | Hospital where radiotherapy was performed[1-3]
+
Refers to radiotherapy targeting the primary tumour.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | uitgebr_chir_code | Code for the most extensive surgical procedure
+
Defined as the most extensive lung surgery performed with the aim of removing the primary tumour.
A carinal resection is considered the most extensive type of lung surgery, followed by pneumonectomy, bilobectomy, sleeve lobectomy, lobectomy, bisegmentectomy, segmentectomy, wedge resection, and lung surgery not otherwise specified.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | uitgebr_chir_dat | Date of the most extensive surgical procedure | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | uitgebr_chir_int | Interval between incidence date and date of the most extensive surgical procedure (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary lung tumour.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | uitgebr_chir_opnameduur | Length of hospital stay related to the most extensive surgical procedure (days)
+
Available from 2011.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | uitgebr_chir_ovl | Death following the most extensive surgical procedure
+
In the case of multiple lung surgeries, mortality is assessed after the most extensive lung surgery.
The value 9 (unknown) may also indicate that it was last established that a patient was still alive less than 90 days after lung surgery, based on the annual linkage with the Municipal Personal Records Database (BRP) (see also the variable vit_stat). In recent registrations, value 9 will therefore occur more frequently.
Note: when death occurs within 30 or 90 days after the most extensive lung surgery, this does not necessarily mean that it was caused by the surgery. Other factors may also have contributed.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | uitgebr_chir_type | Type of the most extensive surgical procedure
+
Defined as the most extensive lung surgery performed with the aim of removing the primary tumour.
A pneumonectomy is considered the most extensive type of lung surgery, followed by bilobectomy, lobectomy, sublobar resection, and unspecified lung surgery.
|
valuelist
+
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treatment data | uitgebr_chir_zkh | Hospital where the most extensive surgical procedure was performed |
valuelist
+
|